Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction
- 18 February 2016
- journal article
- clinical trial
- Published by Taylor & Francis in The Aging Male
- Vol. 19 (2) , 128-133
Abstract
This study analyzed the effects of dutasteride on lower urinary tract symptoms based on the association between changes in the total testosterone (TT)/dihydrotestosterone (DHT) levels and total prostate volume (TPV) reduction. Sixty participants diagnosed with benign prostatic hyperplasia were given 0.5 mg of dutasteride daily for 52 weeks. Measures of TT and DHT levels, TPV and uroflowmetry were obtained before and after dutasteride treatment. Forty-three patients demonstrated a TPV reduction of ≥5% (Group 1), whereas the remaining 17 patients demonstrated a TPV reduction of <5% (Group 2). DHT suppression and DHT/TT ratio at baseline were significantly higher in Group 1 than Group 2. International Prostate Symptom Scores (IPSS) and uroflowmetry were significantly improved in both groups. In Group 2, nine patients demonstrated some improvement in IPSS (Group 2A), whereas eight did not (Group 2B). The rate of TT increase and improvement in voiding symptoms were significantly higher in Group 2A than Group 2B. Dutasteride-induced TPV reduction is dependent on individual 5-α reductase inhibitor activity. Some patients demonstrating smaller dutasteride-induced TPV reduction may experience an improvement in voiding symptoms owing to an increased level of testosterone.Keywords
This publication has 28 references indexed in Scilit:
- Evaluation of Intravesical Prostatic Protrusion as a Predictor of Dutasteride-Resistant Lower Urinary Tract Symptoms/Benign Prostatic Enlargement With a High Likelihood of Surgical InterventionUrology, 2015
- 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen levelJournal of the Formosan Medical Association, 2015
- Development of a new gas chromatography–mass spectrometry (GC–MS) methodology for the evaluation of 5α-reductase activityTalanta, 2013
- Dutasteride, who is it more effective for? Second to fourth digit ratio and the relationship with prostate volume reduction by dutasteride treatmentBJU International, 2012
- Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasiaInternational Journal of Urology, 2009
- Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: Interference and comparison with established methodsSteroids, 2008
- Decline of plasma 5α-dihydrotestosterone (DHT) levels upon testosterone administration to elderly men with subnormal plasma testosterone and high DHT levelsAndrologia, 2008
- Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasiaUrology, 2004
- Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasiaUrology, 2002
- Estimate Criteria for Efficacy of Treatment in Benign Prostatic HyperplasiaInternational Journal of Urology, 1996